Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rohto Pharmaceutical Co., Ltd. has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 examiners across 6 art units, showing that examiner diversity is broader than art-unit diversity and that some technical groups contain more than one matter.
HOLLOMAN, NANNETTE is the busiest examiner, with 1 pending matter. No examiner holds a larger identified concentration, so prosecution oversight should prioritize consistent portfolio positioning while tailoring responses to each examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (56%) |
| §102 only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
| RIGA, MICHAEL ANGELO | 1 | 56.2% | +63.0% |
| EBBINGHAUS, BRIANA NOEL | 1 | 59.7% | +63.0% |
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 51.6% | +29.8% |
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| WELLES, COLMAN THOMAS | 1 | 26.9% | +65.7% |
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018105 | Aqueous Composition | WELLES, COLMAN THOMAS | 49d overdue |
| 18832346 | COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD | EBBINGHAUS, BRIANA NOEL | — |
| 18703041 | OPHTHALMIC COMPOSITION | KRISHNAN, GANAPATHY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018105 | Aqueous Composition | WELLES, COLMAN THOMAS | 49d overdue |
| 18709382 | OIL-BASED SOLID COMPOSITION FOR EXTERNAL USE | ABBAS, ABDULRAHMAN MUSTAFA | 39d |
| 19105896 | THERAPEUTIC AGENT FOR RENAL DISEASE AND RENAL FUNCTION-IMPROVING AGENT | HOLLOMAN, NANNETTE | — |
| 18832341 | COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD | RIGA, MICHAEL ANGELO | — |
| 18832346 | COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD | EBBINGHAUS, BRIANA NOEL | — |
| 17918390 | AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1612 | 3 |
| 1632 | 1 |
| 1693 | 1 |
| 1617 | 1 |
| 1638 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19105896 | THERAPEUTIC AGENT FOR RENAL DISEASE AND RENAL FUNCTION-IMPROVING AGENT | HOLLOMAN, NANNETTE | 1612 | §103 | Non-Final OA | — | Pending | Feb 24, 2025 |
| 18832341 | COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD | RIGA, MICHAEL ANGELO | — | §102Other | Non-Final OA | — | Pending | Feb 04, 2025 |
| 18832346 | COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD | EBBINGHAUS, BRIANA NOEL | 1632 | §102§103 | Final Rejection | — | Pending | Jul 23, 2024 |
| 18709382 | OIL-BASED SOLID COMPOSITION FOR EXTERNAL USE | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | 39d | Pending | May 10, 2024 |
| 18703041 | OPHTHALMIC COMPOSITION | KRISHNAN, GANAPATHY | 1693 | §102§103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18018108 | Aqueous Composition | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Jan 26, 2023 |
| 18018105 | Aqueous Composition | WELLES, COLMAN THOMAS | 1612 | §103DP | Non-Final OA | 49d overdue | Pending | Jan 26, 2023 |
| 17918390 | AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Oct 12, 2022 |
| 17788378 | Aqueous Composition | NOLAN, JASON MICHAEL | 1623 | §103 | Final Rejection | — | Pending | Jun 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRohto Pharmaceutical Co., Ltd. has 9 pending office actions as of October 2026, spread across 6 art units and 9 examiners.
Nannette Holloman has the most, with 1 of Rohto Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
